Key facts
- ProLynx’s last known valuation is $129.0M (Dec 2025).
- It has raised $70.1M; the latest was Later Stage VC ($70.0M) in Dec 2025.
- Notable investors include US National Science Foundation, OrbiMed, 5AM Ventures, Monograph Capital, National Institute of Diabetes and Digestive and Kidney Diseases.
- ProLynx has filed 1 Form D with the SEC, most recently Sep 2020 ($55K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ProLynx
- ·The full record, as it builds
Funding rounds
No funding rounds for ProLynx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProLynx
Operator of a biotechnology company intended to develop ultra-long-acting medicines for obesity and other metabolic diseases. The company's system offers linker technologies that are pre-programmed to cleave at different rates to allow the controlled, predictable, and sustained release of native, active drugs, peptides, proteins, and small molecules from circulating and semi-solid macromolecular conjugates for weeks to months, enabling clients to sustain desired levels of drugs for predictable periods.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2009
- Employees
- 10
- Website
- prolynxinc.com/
- Ownership
- Privately Held (backing)
ProLynx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProLynx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProLynx in its N-PORT filings yet. We sweep new filings monthly.